[Yokohama, Japan, April 8, 2024] – Juro Sciences, a clinical stage biopharmaceutical company focused on innovative solutions for underactive bladder (UAB), announced today the successful completion of its JPY 750 million Series A financing round. The funding will be used to accelerate the development of SFG-02, a promising preclinical candidate designed to revolutionize the treatment landscape for UAB.

Underactive bladder, a condition characterized by diminished bladder contraction and incomplete emptying, represents a significant unmet medical need affecting millions worldwide. Juro Sciences’ cutting-edge approach aims to address this challenge by targeting the underlying mechanisms contributing to UAB.

“We are thrilled to have secured this substantial investment, which reflects the confidence of our investors in the potential of SFG-02 and our overall mission to transform the lives of patients with underactive bladder,” said Dr. Hiroshi Nagabukuro, CEO of Juro Sciences. “This funding will fuel our efforts to advance SFG-02 through preclinical and clinical development and move closer to offering a much-needed breakthrough therapy for individuals living with this condition.”

The investment is led by Miyako Capital with the participation of Mitsubishi UFJ Capital, SMBC Venture Capital and FFG Venture Business Partners, and shows their strong support for Juro Sciences’ innovative approach and the immense market opportunity for effective UAB treatments.. The funding will enable the company to expand its research and development initiatives, conduct a novel formulation development, nonclinical studies, and lay the groundwork for future clinical trials.

“We are excited about the progress of SFG-02 and the potential it holds to significantly improve the quality of life for patients grappling with underactive bladder,” commented Dr. Hiroyuki Misawa, Partner of Miyako Capital. “Juro Sciences’ dedication to scientific excellence and patient-centric innovation aligns with our investment philosophy, and we look forward to the continued success of this groundbreaking program.”

SFG-02 leverages Juro Sciences’ extensive drug discovery expertise, which combines advanced drug delivery systems with targeted therapeutic mechanisms to optimize efficacy and minimize side effects. The company’s commitment to rigorous research, regulatory compliance, and strategic partnerships positions it as a frontrunner in the pursuit of new UAB therapies.

About Juro Sciences:

Juro Sciences is a biopharmaceutical company dedicated to developing innovative therapies for UAB. Leveraging cutting-edge science and a patient-centric approach, Juro Sciences is committed to improving outcomes and enhancing the quality of life for individuals affected by these conditions.

About SFG-02:

SFG-02 is a novel small molecule enzyme inhibitor with a transformative non-oral formulation, being developed for the treatment of UAB. Multiple preclinical studies demonstrated significant selectivity to the molecular target and optimal efficacy in animal models of UAB. Nonclinical toxicology and ADME data support IND filing and initiation of phase 1 study in healthy volunteers.

For media inquiries or further information about Juro Sciences and SFG-02, please contact:

info@sfgsci.com